Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of regorafenib, immune checkpoint inhibitors, and regional chemotherapy for unresectable or metastatic cholangiocarcinoma
ChiCTR2100053025Phase 4Recruiting
- Sponsor
- PLA General Hospital Fifth Medical Center
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of regorafenib in cholangiocarcinoma (CCA), sponsored by PLA General Hospital Fifth Medical Center. Primary endpoint: Progression-free survival. Started Nov 2021; status: recruiting.
02
Drugs
regorafenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2100053025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053025.